About
About BrightGene Bio-Medical Technology Co., Ltd
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, including metabolism, oncology, respiratory, immunosuppression, antiviral, antifungal, antitumor, cerebrovascular, iron supplement, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, digestion, and others. In addition, the company is involved in technology research and development; transfer of biomedical products; import, export, wholesale, and retail of medicines; production and operation of medical devices; and technical services. BrightGene Bio-Medical Technology Co., Ltd. was founded in 2001 and is based in Suzhou, China.
Visit company website
5 years, 5 months ago
BrightGene Bio-Medical Technology Co., Ltd is currently in a long term downtrend where the price is trading 17.1% below its 200 day moving average.
From a valuation standpoint, the stock is 128.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 22.0.
BrightGene Bio-Medical Technology Co., Ltd's total revenue rose by 44.9% to $275M since the same quarter in the previous year.
Its net income has increased by 1.8% to $48M since the same quarter in the previous year.
Based on the above factors, BrightGene Bio-Medical Technology Co., Ltd gets an overall score of 2/5.